Michael J. Fisher, M.D.
Professor of Pediatrics (Oncology) at the Children's Hospital of Philadelphia
Attending Physician, Center for Childhood Cancer Research and Division of Oncology, Children's Hospital of Philadelphia
Member, Cancer Center, University of Pennsylvania
Director, Neurofibromatosis Program, Children’s Hospital of Philadelphia
Chief, Neuro-Oncology Section, Division of Oncology, Children’s Hospital of Philadelphia
Hubert J.P. and Anne Faulkner Schoemaker Endowed Chair in Pediatric Neuro-Oncology, Children’s Hospital of Philadelphia
Department: Pediatrics
Contact information
Center for Childhood Cancer Research and Division of Oncology
The Children’s Hospital of Philadelphia
3500 Civic Center Blvd.
HUB-3589
Philadelphia, PA 19104
The Children’s Hospital of Philadelphia
3500 Civic Center Blvd.
HUB-3589
Philadelphia, PA 19104
Office: (215)590-2800
Email:
fisherm@email.chop.edu
fisherm@email.chop.edu
Education:
Eberhard-Karls Universitaet, Tubingen, Germany, 1987.
B.A. (Psychology, Summa cum Laude)
Amherst College, 1989.
M.D.
Harvard Medical School (cum Laude), 1994.
Permanent linkEberhard-Karls Universitaet, Tubingen, Germany, 1987.
B.A. (Psychology, Summa cum Laude)
Amherst College, 1989.
M.D.
Harvard Medical School (cum Laude), 1994.
Selected Publications
Estrela T, Truong S, Garcia A, He J, Ying G-S, Devakandan K, Reginald AR, Fisher MJ, Liu GT, Ullrich NJ, Avery RA, Heidary G: The Relationship between Choroidal Abnormalities and Visual Outcomes in Pediatric Patients with NF1-associated Optic Pathway Gliomas: A Longitudinal Study. J Neuro-Ophthalmology 44(1): 5-9, 2024.John L, Singh G, Dombi E, Wolters P, Martin S, Baldwin A, Steinberg S, Bernstein J, Whitcomb P, Pichard D, Dufek A, Gillespie A, Heisey K, Bornhorst M, Fisher M, Weiss B, Kim A, Widemann B, Gross A: Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1. Clin Trials 21(2): 189-198, 2024.
Gross AM, Plotkin S, Watts N, Fisher M, Klesse L, Lessing A, McManus M, Larson AN, Oberlander B, Rios J, Sarnoff H, Simpson B, Ullrich N, Stevenson D, on behalf of the REiNS International Collaboration: Potential Endpoints for Assessment of Bone Health in Persons with Neurofibromatosis Type 1. Clinical Trials 21(1): 29-39, 2024.
Jiang Z, Parida A, Anwar SM, Tang Y, Roth HR, Fisher MJ, Packer RJ, Avery RA, Linguraru MG: Automatic Visual Acuity Loss Prediction in Children with Optic Pathway Gliomas using Magnetic Resonance Imaging. Annu Int Conf IEEE Eng Med Biol Soc Page: 1-5, July 2023.
Kotch C*, Si S*, Desai K, Caminada P, Lo Russo FM, Li Y, Liu GT, Avery RA, Fisher MJ: The Impact of Changes in Gadolinium-Enhancement on Disease Progression in Children with Neurofibromatosis Type 1-Associated Optic Pathway Glioma: A Retrospective Analysis. J NeuroOncol 164(3): 741-747, 2023.
McCormack SE, Wang Z, Wade KL, Dedio A, Cilenti N, Crowley J, Plessow F, Bamba V, Roizen JD, Jiang Y, Stylli J, Ramakrishnan A, Platt ML, Shekdar K, Fisher MJ, Vetter VL, Hocking M, Xiao R, Lawson EA: A Pilot Randomized Clinical Trial of Intranasal Oxytocin to Promote Weight Loss in Individuals With Hypothalamic Obesity. J Endocr Soc 7(5): bvad037, 2023.
Ahmed A, Fisher MJ, Snyder KM, Smith K, Laskin BL, Perman MJ: Adverse Cutaneous Reactions Associated with MEK Inhibitor Therapy in a Pediatric Population. J Am Acad Dermatol 89(5): 1066-1068, 2023.
Kotch C, Dombi E, Shah AC, Smith K, Brown S, Li Y, Widemann BC, Fisher MJ: Retrospective Cohort Analysis of the Impact of Puberty on Plexiform Neurofibroma Growth in Patients with Neurofibromatosis Type 1. J Pediatrics 260: 113513, 2023.
Kotch C*, Wagner K*, Broad JH, Minturn JE, Phillips P, Li Y, Jacobs IN, Elden LM, Fisher MJ, Belasco JB: Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study. Cancers 15(9): 2621, 2023.
Plotkin SR, Allen J, Dhall G, Campian, JL, Clapp DW, Fisher MJ, Jain RK, Tonsgard J, Ullrich NJ, Thomas C, Edwards LJ, Korf B, Packer R, Karajannis MA, Blakeley JO: Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma. Neuro-Oncol 25(8): 1498-1506, 2023.